Physician profile
Catherine E Benbow
NPI 1831486661
$1,360.77
in general payments reported to CMS, 2019-2025
21 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $53.96 · 2021: $26.63 · 2022: $148 · 2023: $367 · 2024: $332 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $234.47 | 2019-2025 | |
| Lilly USA, LLC | $167.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $162.03 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $123.06 | 2019-2023 | Vaxneuvance, M-M-R II, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $121.38 | 2022-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $106.02 | 2021-2024 | Vraylar |
| Astellas Pharma US INC | $58.74 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $55.80 | 2019-2024 | Breztri, Airsupra |
| Exact Sciences Corporation | $48.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Organon LLC | $48.26 | 2022-2025 | Nexplanon |
| Neurocrine Biosciences, INC. | $31.46 | 2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $30.19 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.32 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $27.32 | 2023-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.96 | 2025 | Caplyta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.02 | 2024 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $17.49 | 2025 | |
| Amgen INC. | $17.43 | 2024 | Repatha |
| Sanofi Pasteur INC. | $15.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.55 | 2024 | Austedo Xr |
| Glaxosmithkline, LLC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Benbow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.